Precision mTOR targeting aims to widen the window in TSC epilepsy

Companies are turning to tuberous sclerosis complex epilepsy as a proving ground for selective mTORC1 inhibitors that could improve on standard-of-care Afinitor. The appeal is straightforward: the target is already de-risked, and success in TSC could translate to a wider set of diseases.

Tuberous sclerosis complex (TSC) is a rare developmental disorder caused by mTOR hyperactivation, leading to multisystem issues such as seizures and widespread hamartomas...